Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis

Blood

Volumn 116, Issue 23, 2010, Pages 5037-5044

  McEachron, Troy A ^a   Pawlinski, Rafal ^a   Richards, Kristy L ^a   Church, Frank C ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; UROKINASE;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; BREAST CARCINOMA; CANCER INVASION; CARCINOMA CELL; CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FIBRINOLYSIS; GOLGI COMPLEX; METASTASIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 78649752975     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-293126     Document Type: Article

References (49)

1. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol. 2006;12(30):4843-4849. (Pubitemid 44323209)
2. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor upregulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010;116(5):815-818.
3. Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69(6):2540-2549.
4. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734-1741.
5. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63(11):2997-3000. (Pubitemid 36667175)
6. Jiang X, Bailly MA, Panetti TS, et al. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004;2(1):93-101.
7. Hu L, Ibrahim S, Liu C, et al. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res. 2009;69(8):3374-3381.
8. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29):4834-4838.
9. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97(10):5255-5260.
10. Versteeg HH, Schaffner F, Kerver M, et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 2008;68(17):7219-7227.
11. Booden MA, Eckert LB, Der CJ, Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol. 2004;24(5):1990-1999.
12. Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009;69(15):6223- 6231.
13. Ludeman MJ, Kataoka H, Srinivasan Y, et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem. 2005;280(13):13122-13128.
14. Bhattacharjee G, Ahamed J, Pawlinski R, et al. Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res. 2008;102(4):457-464. (Pubitemid 351651111)
15. Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313.
16. Mannaioni G, Orr AG, Hamill CE, et al. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem. 2008;283(29):20600-20611.
17. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-1882.
18. Russo A, Soh UJK, Trejo J. Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv. 2009;9(2):87-96.
19. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404(6778):609-613.
20. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113(9):1244-1254.
21. O'Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275(18):13502-13509.
22. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):184-194.
23. Maillard CM, Bouquet C, Petitjean MM, et al. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis. 2008;29(11):2236-2242.
24. Henneke I, Greschus S, Savai R, et al. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med. 2010;181(6):611-619.
25. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 2004;279(30):31735-31744.
26. Sandberg T, Casslén B, Gustavsson B, Benraad TJ. Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis. Biol Reprod. 1998;59(4):759-767.
27. Binder BR, Mihaly J, Prager GW. uPAR-uPAPAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97(3):336-342.
28. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 2007;110(7):2432-2439.
29. Hildenbrand R, Schaaf A, Dorn-Beineke A, et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol. 2009;24(7):869-877.
30. De Cremoux P, Grandin L, Diéras V, et al. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res. 2009;29(5):1475-1482.
31. Albrektsen T, Sørensen BB, Hjortø GM, et al. Transcriptional program induced by factor VIIatissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007;5(8):1588-1597.
32. Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998;58(19):4461-4467.
33. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399-1405.
34. Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17(2):163-170.
35. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335-348.
36. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108.
37. Lou Y, Preobrazhenska O, auf dem Keller U, et al. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev Dyn. 2008;237(10):2755-2768.
38. Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res. 1994;54(12):3300-3304.
39. Orci L, Tagaya M, Amherdt M, et al. Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell. 1991;64(6):1183-1195.
40. Yeaman C, Ayala MI, Wright JR, et al. Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nat Cell Biol. 2004;6(2):106-112.
41. Kaneider NC, Leger AJ, Agarwal A, et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8(12):1303-1312.
42. Awasthi V, Mandal SK, Papanna V, Rao LVM, Pendurthi UR. Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol. 2007;27(6):1447-1455.
43. Morris DR, Ding Y, Ricks TK, et al. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006;66(1):307-314.
44. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518-524.
45. Versteeg HH, Borensztajn KS, Kerver ME, et al. TF:FVIIa-specific activation of CREB upregulates proapoptotic proteins via protease-activated receptor-2. J Thromb Haemost. 2008;6(9):1550-1557.
46. Bohn OL, Nasir I, Brufsky A, et al. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol. 2009;3(2):139-146.
47. Clavel C, Chavanel G, Birembaut P. Detection of the plasmin system in human mammary pathology using immunofluorescence. Cancer Res. 1986;46(11):5743-5747.
48. Xiang M, Gu Y, Zhao F, et al. Mast cell tryptase promotes breast cancer migration and invasion. Oncol Rep. 2010;23(3):615-619.
49. Papachristopoulou G, Avgeris M, Scorilas A. Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost. 2009;101(2):381-387.